Melinta Obtains Ban On Generic Antibiotic Injections In IP Row
By Andrew Karpan · November 18, 2024, 9:17 PM EST
A drugmaker that recently sold a manufacturing facility to Eli Lilly for nearly $1 billion has failed to persuade a federal judge in Chicago to wipe out patents covering a line...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login